<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005">
<channel xmlns:cfi="http://www.microsoft.com/schemas/rss/core/2005/internal" cfi:lastdownloaderror="None">
<title cf:type="text"><![CDATA[《中国临床新医学》杂志编辑部 -->专家论坛·综合介入与外周血管介入]]></title>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Progress in the clinical treatment of Stanford type B aortic dissection]]></title>
<link><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20220902&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>［Abstract］</b>　Aortic dissection(AD), as the most common acute aortic syndrome, has attracted more and more attention in clinical practice with the increasing incidence in recent years. The disease is characterized by rapid onset, rapid progression, extremely high mortality rate, and poor prognosis in late stage for the patients who fail to receive appropriate surgery. Therefore, it is essential for early prevention, diagnosis and treatment of the disease. The treatment and prognosis of AD mainly depend on the involved aortic segments and the time of dissection formation. The location of the rupture also plays a key role in the treatment and prognosis of AD. This paper reviews the progress in the clinical treatment of Stanford type B AD.]]></description>
<pubDate>2022/9/30 11:37:10</pubDate>
<category><![CDATA[专家论坛·综合介入与外周血管介入]]></category>
<author><![CDATA[SHI Ling-hua, JIANG Zhe-yu, WANG Li-zhou, et al.]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SHI Ling-hua, JIANG Zhe-yu, WANG Li-zhou, et al.</atom:name>
</atom:author>
<guid><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20220902&flag=1]]></guid><cfi:id>6</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[A study on the application effect of prevention and control management model based on the construction of NEWS in patients undergoing interventional therapy for fatal bleeding]]></title>
<link><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20220903&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>［Abstract］　Objective</b>　To study the application effect of prevention and control management model based on the construction of National Early Warning Score(NEWS) in patients undergoing interventional therapy for fatal bleeding. <b>Methods</b>　A total of 200 fatal bleeding patients who underwent interventional therapy in a class A tertiary hospital in Hunan province from June 2019 to June 2020 were selected as the research subjects. The patients were randomly divided into observation group(<i>n</i>=100) and control group(<i>n</i>=100). The control group was implemented with routine intervention measures and procedures, while the observation group was implemented with prevention and control management based on NEWS plus the same intervention measures and procedures as the control group. The length of emergency treatment, the incidence of complications and the mortality and shock stage of interventional therapy were compared between the two groups. <b>Results</b>　The pre-examination and triage time, multidisciplinary team reception time, time from admission to B-ultrasonic report, time from admission to laboratory report, emergency stay time and time from admission to the operating room in the observation group was shorter than that in the control group, and the difference was statistically significant(<i>P</i><0.05). The incidence and mortality of complications such as multiple organ dysfunction syndrome(MODS), infection and cardiac arrest in the observation group were lower than those in the control group, and the differences were statistically significant(<i>P</i><0.05). The shock stage at 4 hours after operation in the observation group was better than that in the control group, and the difference was statistically significant(<i>P</i><0.05). <b>Conclusion</b>　The prevention and control management model of fatal bleeding based on NEWS is helpful for medical staff to identify the risk of fatal bleeding early. The corresponding emergency prevention and control measures based on the scoring values can significantly shorten the emergency time of the interventional patients, reduce the incidence of postoperative complications and mortality, and improve the shock stage and prognosis of the postoperative patients.]]></description>
<pubDate>2022/9/30 11:37:10</pubDate>
<category><![CDATA[专家论坛·综合介入与外周血管介入]]></category>
<author><![CDATA[HU Qin, XIANG Hua, WANG Qing, et al.]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HU Qin, XIANG Hua, WANG Qing, et al.</atom:name>
</atom:author>
<guid><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20220903&flag=1]]></guid><cfi:id>5</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Recent advances in drug selection for the treatment of hepatocellular carcinoma by transarterial chemoembolization with drug-eluting beads]]></title>
<link><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20220904&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>［Abstract］</b>　Hepatocellular carcinoma(HCC) is a malignant tumor with high morbidity and mortality. How to effectively improve the treatment effect of HCC is an important problem to be solved urgently in clinical practice.Transarterial chemoembolization(TACE) is the preferred treatment for the intermediate and unresectable early-stage HCC. Drug-eluting beads TACE(DEB-TACE) is one of the most commonly applied types of TACE. Compared with conventional TACE, DEB-TACE can significantly reduce the incidence of adverse reactions, but does not significantly improve the survival time of the patients. Therefore, how to effectively improve the efficacy of DEB-TACE is a problem that is worthy of attention. With target therapies and immunotherapies showing continuously explicit promising clinical benefits in the patients with HCC, it is a new choice for drug-eluting beads to break through the limitation that only water-soluble chemotherapy drugs can be loaded and to explore new drug-loading properties. It is also a new direction to improve the overall efficacy of DEB-TACE.]]></description>
<pubDate>2022/9/30 11:37:10</pubDate>
<category><![CDATA[专家论坛·综合介入与外周血管介入]]></category>
<author><![CDATA[WANG Ruo-su, LIU Zong-yi, LIU Yue, et al.]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Ruo-su, LIU Zong-yi, LIU Yue, et al.</atom:name>
</atom:author>
<guid><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20220904&flag=1]]></guid><cfi:id>4</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Effects of linear alkyl grafted graphene oxide for embolization on immune cells]]></title>
<link><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20220905&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>［Abstract］　Objective</b>　To investigate the effects of linear alkyl grafted graphene oxide(GO-C18) nanocarriers for embolization on immune cells. <b>Methods</b>　Macrophages were extracted from the bone marrow of BALB/c mice for culture, and lymphocytes were extracted from the spleen of BALB/c mice for culture and cell sorting. Macrophages, T cells, and B cells in logarithmic phase were treated with 10 μg/ml graphene oxide(GO), 10 μg/ml GO-C18 and equal volume of phosphate buffer saline(PBS) for a certain time. Then, the activation of macrophages, T cells and B cells were detected by flow cytometry and the function of macrophages was analysed. The macrophages in logarithmic phase were treated with different concentrations of GO, GO-C18(200 μg/ml, 100 μg/ml, 50 μg/ml, 10 μg/ml) and equal volume of PBS for a certain time to detect the phagocytic ability of macrophages. A mouse macrophage-leukemia cell(L1210 cell) co-culture system was established and treated with 10 μg/ml GO, GO-C18 and equal volume of PBS for a certain time to detect the phagocytic ability of macrophages. <b>Results</b>　The expressions of markers such as CD69, CD80, CD86, signal regulatory protein alpha(SIRPα), and major group histocompatibility complex Ⅱ(MHCⅡ) on macrophages were stable after treatment with 10 μg/ml GO-C18 for 48 h, indicating that macrophage activation, M1 phenotype, M2 phenotype, and antigen-presenting ability were not significantly affected. The expressions of CD69 on T cells and B cells were stable after treatment with 10 μg/ml GO-C18 for 72 hours, indicating that the activations of T cells and B cells were not significantly affected. The phagocytic function of macrophages was not significantly affected after treatment with 10 μg/ml GO-C18 for 24 hours. <b>Conclusion</b>　This study preliminarily demonstrates that GO-C18 has no significant adverse effects on the function and activation of macrophages and the activations of T cells and B cells.]]></description>
<pubDate>2022/9/30 11:37:10</pubDate>
<category><![CDATA[专家论坛·综合介入与外周血管介入]]></category>
<author><![CDATA[ZENG Lin-yuan, WANG Li-xiang, ZHANG Gui-yuan, et al.]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZENG Lin-yuan, WANG Li-xiang, ZHANG Gui-yuan, et al.</atom:name>
</atom:author>
<guid><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20220905&flag=1]]></guid><cfi:id>3</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis on the clinical effect of internal carotid artery covered stent implantation in application for massive hemorrhage of nasopharyngeal carcinoma]]></title>
<link><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20220906&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>［Abstract］　Objective</b>　To analyze the clinical effect of internal carotid artery covered stent implantation in application for massive hemorrhage of nasopharyngeal carcinoma. <b>Methods</b>　The clinical data of 16 patients with nasopharyngeal carcinoma and massive hemorrhage who were admitted to the People′s Hospital of Guangxi Zhuang Autonomous Region from May 2014 to August 2022 and received interventional covered stent implantation were retrospectively analyzed. The patients′ clinical characteristics, interventional treatment methods and clinical efficacy were analyzed. <b>Results</b>　Among the 16 patients with massive hemorrhage of nasopharyngeal carcinoma, twelve cases were cured and discharged from the hospital; four cases suffered from rebleeding after operation, and 4 cases died. One case had small-scale cerebral infarction; one case had oculomotor nerve palsy and recovered one month later. <b>Conclusion</b>　Nasopharyngeal carcinoma patients complicated with massive hemorrhage have high mortality and poor prognosis. Among the interventional methods, the internal carotid artery and common carotid artery covered stent implantation has a better hemostatic effect. This interventional method is safe and effective, and the patients have a better quality of life after the operation. However, the long-term efficacy still needs to be further studied.]]></description>
<pubDate>2022/9/30 11:37:10</pubDate>
<category><![CDATA[专家论坛·综合介入与外周血管介入]]></category>
<author><![CDATA[FENG Zhi-bo, CUI Xu-dong, LIANG Jing-chang, et al.]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>FENG Zhi-bo, CUI Xu-dong, LIANG Jing-chang, et al.</atom:name>
</atom:author>
<guid><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20220906&flag=1]]></guid><cfi:id>2</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis on the factors affecting the recurrence of femoropopliteal arteriosclerosis obliterans of lower extremity after interventional therapy]]></title>
<link><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20220907&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>［Abstract］　Objective</b>　To analyse the factors affecting the recurrence of femoropopliteal arteriosclerosis obliterans(ASO) of lower extremity after interventional therapy. <b>Methods</b>　The clinical data of 96 patients with femoropopliteal ASO who received interventional therapy in the Second People′s Hospital of Hefei from May 2018 to February 2020 were collected. The patients were followed up for 2 years by outpatient visit and telephone to evaluate the vascular patency of the affected limbs. Binary logistic regression analysis method was used to analyse the risk factors for recurrence after interventional therapy, and receiver operating characteristic(ROC) curve was used to analyse the efficacy of target variables to predict the recurrence of ASO after interventional therapy. <b>Results</b>　The recurrence rate was 44.8%(43/96) 2 years after interventional therapy. The results of univariate analysis showed that Trans-Atlantic Inter-Society Consensus Ⅱ(TASC Ⅱ) type, monocyte, red blood cell distribution width, glucose, cystatin C and homocysteine were the risk factors for postoperative recurrence(<i>P</i><0.05). The results of multivariate binary logistic regression showed that TASC Ⅱ type(<i>OR</i>=3.334, 95%<i>CI</i>=1.579-7.039, <i>P</i>=0.002) and cystatin C(<i>OR</i>=3.108, 95%<i>CI</i>=1.149-8.406, <i>P</i>=0.025) were the independent risk factors for postoperative recurrence, and mean corpuscular volume(<i>OR</i>=0.895, 95%<i>CI</i>=0.806-0.995, <i>P</i>=0.040) was the independent protective factor for postoperative recurrence(<i>P</i><0.05). The results of ROC curve analysis showed that the three combined indicators of TASC Ⅱ type, cystatin C and mean corpuscular volume could predict the recurrence after interventional therapy. <b>Conclusion</b>　TASC Ⅱ type and cystatin C combined with mean corpuscular volume can have certain predictive value for the prognosis of the patients. The risk of recurrence after interventional therapy can be reduced by protecting renal function and by reducing cystatin C or by increasing mean corpuscular volume.]]></description>
<pubDate>2022/9/30 11:37:10</pubDate>
<category><![CDATA[专家论坛·综合介入与外周血管介入]]></category>
<author><![CDATA[JIA Xu, PAN Sheng-quan, XIANG Ting-miao, et al.]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>JIA Xu, PAN Sheng-quan, XIANG Ting-miao, et al.</atom:name>
</atom:author>
<guid><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20220907&flag=1]]></guid><cfi:id>1</cfi:id><cfi:read>true</cfi:read></item>
</channel>
</rss>